Home' Australian Pharmacist : Australian Pharmacist August 2016 Contents Australian Pharmacist August 2016 I © Pharmaceutical Society of Australia Ltd.
CONTINUING PROFESSIONAL DEVELOPMENT
pharmacy business should grow as a
result of an increase in customer loyalty,
prescriptions and product sales.
Providing an eczema service
Pharmacists who are planning to
implement any professional service in
their pharmacy will need to consider
the availability of suitable consultation
space, workflow, staff training, and the
availability of pharmacists. All of these
factors will need to be considered before
implementing an eczema service.
Community pharmacy is ideally
positioned to offer an eczema service
that consists of advice and supply of
eczema-related products. Patients
with eczema need to regularly visit
their local community pharmacy to
collect prescription or non-prescription
medicines used in the management of
their eczema. This presents a significant
opportunity for pharmacists to influence
the health outcomes of this group of
The following are examples of activities
that can be undertaken in the pharmacy
as part of an eczema service:
Communicating to customers that
the pharmacy staff can provide advice
about and products for eczema.
Promotional material could be small
callouts on shelves or on external
Providing written action plans,
including MedsChecks. Considering
the complexity of eczema
management, a written action plan
may assist some patients in managing
Referral. It is essential for pharmacists
to develop professional relationships
with local doctors, including
specialists, to establish an appropriate
referral network. Use of technology,
e.g. GuildCare can also assist
pharmacists in writing and recording
referrals for patients with eczema.
Eczema is a common condition
that requires patients to regularly
visit their community pharmacy for
prescribed medicines and over-the-
counter skincare products. This places
pharmacists in an ideal position to
provide an eczema service, thereby
improving clinical outcomes for eczema
patients and helping to grow their
1. Better Health Channel. Eczema (atopic dermatitis).
2015. At: www.betterhealth.vic.gov.au/health/
2. Australasian Society of Clinical Immunology and Allergy
(ASCIA). Information for patients, consumers and carers.
Eczema (atopic dermatitis). 2013. At: www.allergy.org.au/
3. Education and adherence to therapy. In: Atopic eczema in
children (NICE clinical guideline 57). London, UK: National
Collaborating Centre for Women’s and Children’s Health.
2007. At: www.ncbi.nlm.nih.gov/books/NBK49374/
4. Woodhead M. Steroid phobia undermining child eczema
care. Australian Doctor. 2015. At: www.australiandoctor.
5. Sansom LN, ed. Australian pharmaceutical formulary and
handbook. 23rd edn. Canberra: Pharmaceutical Society of
6. Atopic dermatitis [revised Nov 2015]. In: eTG complete.
Melbourne: Therapeutic Guidelines; 2016.
1. In the management of eczema,
the recommended frequency of
a) Once daily.
b) Twice daily.
c) Two to three times daily.
d) Four or more times daily.
2. One fingertip unit (FTU) of topical
corticosteroid cream is sufficient to
a) One adult hand.
b) One adult palm.
c) Two adult hands.
d) Two adult palms.
3. Community pharmacy has an
important role to play in helping
patients better manage their
a) Providing advice about skin care and
common eczema triggers.
b) Counselling on the correct use of
c) Providing referrals to a doctor when
d) All of the above.
4. Which of the following is NOT an
activity that should be undertaken in
the pharmacy as part of an eczema
a) Training staff to tell customers to apply
corticosteroid creams sparingly.
b) Providing customers with written
action plans to help them manage their
c) Communicating to customers that the
pharmacy offers an eczema service.
d) Establishing good professional
relationships with local doctors.
KEY LEARNING POINTS
Community pharmacy is ideally positioned to offer a professional service for
patients with eczema.
The management of eczema is complex, and adherence to eczema treatment is
often difficult to maintain.
Professional relationships with local doctors and use of technology will facilitate
appropriate referral pathways.
FOR FUNGAL AND
THERE’S ONLY ONE
In a clinical trial, 28% of subjects had a dermatophyte-negative culture
after just one month of treatment1
Mycological cure rate of 62% after just six months of treatment1
60% of subjects showed an overall improvement in total visual assessment
after six months treatment1
Covers and protects the nail Treats the damage
Treats the fungus Easy and convenient to use
Reference: 1. Nasir, A., Swick, L., et al., “Clinical Evaluation of Safety and Efficacy of a New Topical Treatment for Onychomycosis”. J. of Drugs in Dermatology. 2011;10;10;1186-1191.
RestoraNailTM Nail Solution (Poly-ureaurethane 16% in organic solvents, 15mL) is a nail treatment solution for use with nail dystrophy and fungal infections. AFT Pharmaceuticals Pty Ltd, Sydney. ABN 29105636413
RESTORANAILTM is the only product indicated for the
treatment of both damaged nails and fungal nail infection
WITH NO FILING!
1800 2387 4276
Hartley Atkinson M.Pharm, PhD
Founder & CEO, AFT Pharmaceuticals
Links Archive Australian Pharmacist July 2016 Australian Pharmacist September 2016 Navigation Previous Page Next Page